<p>QuidelOrtho Corporation（纳斯达克代码：QDEL - 获取免费报告）董事 Ann Rhoads 于 12 月 10 日星期三购买了 750 股该公司的股票。每股平均成本为 28.27 美元，总价值为 21,202.50 美元。交易完成后，该董事持有公司 15,021 股股票，价值为 424,643.67 美元。这代表其持股比例增加了 5.26%。此次购买在向 SEC 的备案中披露，相关信息可通过此链接获取。</p>
<h2>QuidelOrtho 股票上涨 5.0%</h2>
<ul>
<li>Lucira 股票因 FDA 批准上涨超过 250%，需警惕第 11 章破产</li>
</ul>
<p>在周三的交易时段，纳斯达克 QDEL 上涨了 1.36 美元，达到了 28.80 美元。该公司的股票交易量为 1,427,468 股，而其平均交易量为 1,334,466 股。该公司的市值为 19.6 亿美元，市盈率为-1.69，贝塔值为 0.58。公司的流动比率为 1.78，速动比率为 0.98，债务与股本比率为 1.23。QuidelOrtho Corporation 的 52 周最低价为 19.50 美元，52 周最高价为 49.45 美元。公司的 50 日简单移动平均线为 26.47 美元，200 日简单移动平均线为 27.49 美元。</p>
<p>QuidelOrtho（纳斯达克代码：QDEL - 获取免费报告）最近于 11 月 5 日星期三发布了季度财报。公司报告本季度每股收益为 0.80 美元，超出分析师一致预期的 0.51 美元，超出幅度为 0.29 美元。QuidelOrtho 的股本回报率为 5.75%，净利润率为-42.53%。该公司本季度的收入为 6.999 亿美元，而分析师预期为 6.6745 亿美元。在去年同期，公司每股收益为 0.85 美元。公司的季度收入同比下降了 3.7%。QuidelOrtho 已将其 2025 财年的指引设定为每股收益 2.000-2.150 美元。研究分析师预计 QuidelOrtho Corporation 本财年将发布每股收益 2.3 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师最近对 QDEL 股票发表了评论。Zacks Research 在 10 月 13 日星期一的报告中将 QuidelOrtho 的股票评级从 “持有” 下调至 “强烈卖出”。瑞银集团在 11 月 6 日星期四的研究报告中将 QuidelOrtho 的目标价从 26.00 美元上调至 31.00 美元，并给予该股票 “中性” 评级。摩根大通在 11 月 7 日星期五的研究报告中将 QuidelOrtho 的目标价从 26.00 美元下调至 22.00 美元，并对该股票设定了 “减持” 评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 QuidelOrtho 的 “卖出（e+）” 评级。最后，花旗集团在 10 月 7 日星期二的研究报告中重新发布了 “中性” 评级，并将 QuidelOrtho 的目标价设定为 33.00 美元（之前为 40.00 美元）。两位投资分析师对该股票给予了买入评级，两位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “减持”，共识目标价为 38.20 美元。</p>
<p><strong>阅读我们关于 QuidelOrtho 的最新股票报告</strong></p>
<h2>机构投资者对 QuidelOrtho 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该公司的持股。T. Rowe Price Investment Management Inc.在第一季度将其在 QuidelOrtho 的持股增加了 1.9%。T. Rowe Price Investment Management Inc.目前拥有 11,447,188 股该公司的股票，价值为 400,309,000 美元，在上个季度购买了额外的 208,362 股。Invesco Ltd.在第一季度将其在 QuidelOrtho 的持股增加了 10.6%。Invesco Ltd.目前拥有 3,813,833 股该公司的股票，价值为 133,370,000 美元，在上个季度购买了额外的 366,387 股。Dimensional Fund Advisors LP 在第三季度将其在 QuidelOrtho 的持股增加了 14.0%。Dimensional Fund Advisors LP 目前拥有 2,859,455 股该公司的股票，价值为 84,208,000 美元，在上个季度购买了额外的 350,636 股。State Street Corp 在第二季度将其在 QuidelOrtho 的持股增加了 23.3%。State Street Corp 目前拥有 2,700,940 股该公司的股票，价值为 77,841,000 美元，在此期间购买了额外的 510,291 股。最后，Newtyn Management LLC 在第三季度将其在 QuidelOrtho 的持股增加了 58.3%。Newtyn Management LLC 目前拥有 2,700,000 股该公司的股票，价值为 79,515,000 美元，在上个季度购买了额外的 994,332 股。99.00% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 QuidelOrtho</h2>
<p>（获取免费报告）</p>
<p>QuidelOrtho Corporation 提供诊断测试解决方案。该公司通过实验室、输血医学、现场检测和分子诊断业务部门运营。实验室业务部门提供临床化学实验室仪器和测试，测量体液中的目标化学物质，以评估健康状况和临床管理患者；免疫测定实验室仪器和测试，测量作为抗原在疾病传播中起作用的蛋白质、疾病引发的免疫反应中的抗体或适当器官功能和健康的标志物；检测产品用于检测和监测疾病在多个治疗领域的进展；以及专业的诊断解决方案。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 QuidelOrtho</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>市场动量：三只有望大幅突破的股票</li>
<li>5 个适合股息增长投资者的折扣机会</li>
<li>Casey’s General Stores 将继续上涨的三大理由</li>
<li>什么是特别股息？</li>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 QuidelOrtho 吗？</h2>
<p>在考虑 QuidelOrtho 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 QuidelOrtho 并不在名单上。</p>
<p>虽然 QuidelOrtho 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

QDEL

<p>QuidelOrtho 董事 Ann Rhoads 以每股 28.27 美元购买了 750 股，总计 21,202.50 美元，增加了她的持股比例 5.26%。该交易已在 SEC 文件中披露。QuidelOrtho 的股票上涨了 5.0%，达到了 28.80 美元，市值为 19.6 亿美元。分析师的评级不一，普遍目标价为 38.20 美元。机构投资者已调整其持股，T. Rowe Price 等公司的持股显著增加</p>

<p>QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) Director Ann Rhoads bought 750 shares of the firm's stock in a transaction dated Wednesday, December 10th. The shares were acquired at an average cost of $28.27 per share, with a total value of $21,202.50. Following the completion of the transaction, the director owned 15,021 shares of the company's stock, valued at $424,643.67. This represents a 5.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>QuidelOrtho Corporation（纳斯达克代码：QDEL - 获取免费报告）董事 Ann Rhoads 于 12 月 10 日星期三购买了 750 股该公司的股票。每股平均成本为 28.27 美元，总价值为 21,202.50 美元。交易完成后，该董事持有公司 15,021 股股票，价值为 424,643.67 美元。这代表其持股比例增加了 5.26%。此次购买在向 SEC 的备案中披露，相关信息可通过此链接获取。</p>
</div><h2>QuidelOrtho Stock Up 5.0%</h2>
<div class="lb-trans"><h2>QuidelOrtho 股票上涨 5.0%</h2>
</div><ul>
<li>Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11</li>
</ul>
<div class="lb-trans"><ul>
<li>Lucira 股票因 FDA 批准上涨超过 250%，需警惕第 11 章破产</li>
</ul>
</div><p>NASDAQ QDEL traded up $1.36 during trading hours on Wednesday, hitting $28.80. The company's stock had a trading volume of 1,427,468 shares, compared to its average volume of 1,334,466. The company has a market capitalization of $1.96 billion, a PE ratio of -1.69 and a beta of 0.58. The company has a current ratio of 1.78, a quick ratio of 0.98 and a debt-to-equity ratio of 1.23. QuidelOrtho Corporation has a 52 week low of $19.50 and a 52 week high of $49.45. The company's 50-day simple moving average is $26.47 and its two-hundred day simple moving average is $27.49.</p>
<div class="lb-trans"><p>在周三的交易时段，纳斯达克 QDEL 上涨了 1.36 美元，达到了 28.80 美元。该公司的股票交易量为 1,427,468 股，而其平均交易量为 1,334,466 股。该公司的市值为 19.6 亿美元，市盈率为-1.69，贝塔值为 0.58。公司的流动比率为 1.78，速动比率为 0.98，债务与股本比率为 1.23。QuidelOrtho Corporation 的 52 周最低价为 19.50 美元，52 周最高价为 49.45 美元。公司的 50 日简单移动平均线为 26.47 美元，200 日简单移动平均线为 27.49 美元。</p>
</div><p>QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.29. QuidelOrtho had a positive return on equity of 5.75% and a negative net margin of 42.53%.The firm had revenue of $699.90 million during the quarter, compared to analyst estimates of $667.45 million. During the same period in the previous year, the company posted $0.85 EPS. The company's revenue for the quarter was down 3.7% on a year-over-year basis. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. Research analysts anticipate that QuidelOrtho Corporation will post 2.3 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>QuidelOrtho（纳斯达克代码：QDEL - 获取免费报告）最近于 11 月 5 日星期三发布了季度财报。公司报告本季度每股收益为 0.80 美元，超出分析师一致预期的 0.51 美元，超出幅度为 0.29 美元。QuidelOrtho 的股本回报率为 5.75%，净利润率为-42.53%。该公司本季度的收入为 6.999 亿美元，而分析师预期为 6.6745 亿美元。在去年同期，公司每股收益为 0.85 美元。公司的季度收入同比下降了 3.7%。QuidelOrtho 已将其 2025 财年的指引设定为每股收益 2.000-2.150 美元。研究分析师预计 QuidelOrtho Corporation 本财年将发布每股收益 2.3 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have recently commented on QDEL shares. Zacks Research downgraded shares of QuidelOrtho from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Monday, October 13th. UBS Group upped their price objective on shares of QuidelOrtho from $26.00 to $31.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. JPMorgan Chase &amp; Co. cut their target price on QuidelOrtho from $26.00 to $22.00 and set an &#34;underweight&#34; rating on the stock in a research note on Friday, November 7th. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of QuidelOrtho in a research report on Wednesday, October 8th. Finally, Citigroup reissued a &#34;neutral&#34; rating and issued a $33.00 price objective (down previously from $40.00) on shares of QuidelOrtho in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $38.20.</p>
<div class="lb-trans"><p>几位分析师最近对 QDEL 股票发表了评论。Zacks Research 在 10 月 13 日星期一的报告中将 QuidelOrtho 的股票评级从 “持有” 下调至 “强烈卖出”。瑞银集团在 11 月 6 日星期四的研究报告中将 QuidelOrtho 的目标价从 26.00 美元上调至 31.00 美元，并给予该股票 “中性” 评级。摩根大通在 11 月 7 日星期五的研究报告中将 QuidelOrtho 的目标价从 26.00 美元下调至 22.00 美元，并对该股票设定了 “减持” 评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 QuidelOrtho 的 “卖出（e+）” 评级。最后，花旗集团在 10 月 7 日星期二的研究报告中重新发布了 “中性” 评级，并将 QuidelOrtho 的目标价设定为 33.00 美元（之前为 40.00 美元）。两位投资分析师对该股票给予了买入评级，两位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “减持”，共识目标价为 38.20 美元。</p>
</div><p><strong>Read Our Latest Stock Report on QuidelOrtho</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 QuidelOrtho 的最新股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On QuidelOrtho</h2>
<div class="lb-trans"><h2>机构投资者对 QuidelOrtho 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its stake in QuidelOrtho by 1.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 11,447,188 shares of the company's stock worth $400,309,000 after purchasing an additional 208,362 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of QuidelOrtho by 10.6% in the 1st quarter. Invesco Ltd. now owns 3,813,833 shares of the company's stock worth $133,370,000 after purchasing an additional 366,387 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in QuidelOrtho by 14.0% in the third quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company's stock worth $84,208,000 after buying an additional 350,636 shares in the last quarter. State Street Corp increased its stake in QuidelOrtho by 23.3% in the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company's stock worth $77,841,000 after purchasing an additional 510,291 shares during the period. Finally, Newtyn Management LLC lifted its position in QuidelOrtho by 58.3% in the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company's stock valued at $79,515,000 after purchasing an additional 994,332 shares during the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该公司的持股。T. Rowe Price Investment Management Inc.在第一季度将其在 QuidelOrtho 的持股增加了 1.9%。T. Rowe Price Investment Management Inc.目前拥有 11,447,188 股该公司的股票，价值为 400,309,000 美元，在上个季度购买了额外的 208,362 股。Invesco Ltd.在第一季度将其在 QuidelOrtho 的持股增加了 10.6%。Invesco Ltd.目前拥有 3,813,833 股该公司的股票，价值为 133,370,000 美元，在上个季度购买了额外的 366,387 股。Dimensional Fund Advisors LP 在第三季度将其在 QuidelOrtho 的持股增加了 14.0%。Dimensional Fund Advisors LP 目前拥有 2,859,455 股该公司的股票，价值为 84,208,000 美元，在上个季度购买了额外的 350,636 股。State Street Corp 在第二季度将其在 QuidelOrtho 的持股增加了 23.3%。State Street Corp 目前拥有 2,700,940 股该公司的股票，价值为 77,841,000 美元，在此期间购买了额外的 510,291 股。最后，Newtyn Management LLC 在第三季度将其在 QuidelOrtho 的持股增加了 58.3%。Newtyn Management LLC 目前拥有 2,700,000 股该公司的股票，价值为 79,515,000 美元，在上个季度购买了额外的 994,332 股。99.00% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About QuidelOrtho</h2>
<div class="lb-trans"><h2>关于 QuidelOrtho</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.</p>
<div class="lb-trans"><p>QuidelOrtho Corporation 提供诊断测试解决方案。该公司通过实验室、输血医学、现场检测和分子诊断业务部门运营。实验室业务部门提供临床化学实验室仪器和测试，测量体液中的目标化学物质，以评估健康状况和临床管理患者；免疫测定实验室仪器和测试，测量作为抗原在疾病传播中起作用的蛋白质、疾病引发的免疫反应中的抗体或适当器官功能和健康的标志物；检测产品用于检测和监测疾病在多个治疗领域的进展；以及专业的诊断解决方案。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than QuidelOrtho</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>What is a Special Dividend?</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 QuidelOrtho</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>市场动量：三只有望大幅突破的股票</li>
<li>5 个适合股息增长投资者的折扣机会</li>
<li>Casey’s General Stores 将继续上涨的三大理由</li>
<li>什么是特别股息？</li>
<li>黄金交叉警报：三只具有重大上涨潜力的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in QuidelOrtho Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 QuidelOrtho 吗？</h2>
</div><p>Before you consider QuidelOrtho, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 QuidelOrtho 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 QuidelOrtho 并不在名单上。</p>
</div><p>While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 QuidelOrtho 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部买入：QuidelOrtho（NASDAQ:QDEL）董事购入价值 21,202.50 美元的股票